Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-80
SponsorNational Taiwan University Hospital

About this trial

The aim of this study is to evaluate the impact of artificial intelligence (AI) assistance during routine upper endoscopy on gastric cancer-specific mortality. We hypothesize that AI-assisted endoscopic interpretation can further reduce gastric cancer-related mortality through two mechanisms: (1) improved detection of H. pylori infection, facilitating timely eradication therapy and subsequent prevention of gastric carcinogenesis; and (2) earlier identification of premalignant gastric conditions, enabling appropriate surveillance endoscopy and earlier detection of gastric cancer. The primary endpoint is gastric cancer-specific mortality.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 20-80

Scheduled endoscopy

Disqualifiers

None

Trial population

This study will invite patients who need to undergo upper gastrointestinal endoscopy.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Routine endoscopy with artificial intelligence-assisted interpretation

    Other intervention

    (1) Improved detection of H. pylori infection, leading to timely eradication therapy. (2) Earlier identification of premalignant gastric conditions, facilitating appropriate surveillance endoscopy.

Treatment groups

6,000 Participants
are divided into 2 treatment groups
Group A: Routine endoscopy alone0 interventions
Group B: Routine endoscopy with artificial intelligence-assisted interpretation1 intervention

Trial outcomes

Primary outcomes

1

Gastric cancer-specific mortality

The primary endpoint is gastric cancer-specific mortality.

Time frame
Up to 5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.